Top

American Journal of Cardiovascular Drugs

Published in:

24-12-2023 | Rivaroxaban | Original Research Article

Rivaroxaban Plasma Concentration and Clinical Outcomes on Older Patients with Non-valvular Atrial Fibrillation and Pulmonary Infection

Authors: Yan Yu, Haobin Li, Jing Liu, Qing Liang, Juan Xie, Guangchun Sun

Published in: American Journal of Cardiovascular Drugs | Issue 1/2024

Abstract

Introduction

Infection may induce thrombotic and hemorrhagic events; however, it is currently unclear whether the inflammatory response affects the coagulation function and the clinical efficacy and safety of rivaroxaban in older patients with non-valvular atrial fibrillation (NVAF).

Objective

This project aimed to assess the effectiveness and safety of the non-vitamin K antagonist oral anticoagulant rivaroxaban in older patients with NVAF complicated by infection, and to provide a basis for possible drug dose adjustment.

Methods

A total of 152 NVAF patients aged ≥ 65 years admitted to the Fifth People’s Hospital of Shanghai from June 2020 to May 2022 were included in this prospective, observational study. The changes in steady-state plasma concentration of rivaroxaban and FXa inhibition rate were compared between patients with and without infection, and the impact on the occurrence of infection, thrombotic events, and bleeding events was compared through 1-year follow-up.

Results

Our results showed that patients in the infection group had abnormal inflammation markers, as well as an increased occurrence of bleeding and thrombotic events during hospitalization and follow-up. The high incidence of bleeding events in patients was closely related to the occurrence of infection, lymphocyte reduction, and increased neutrophil-lymphocyte ratio. The increase in thrombotic events was related to a decrease in rivaroxaban plasma concentration. Bleeding events in patients taking anticoagulant drugs are not necessarily due to drug accumulation.

Conclusions

Timely control of infection, assessment of bleeding and thrombotic risks, and selection of appropriate anticoagulation treatment strategies should be made in older NVAF patients who develop pulmonary infection.

Clinical Trials Registration

Chinese Clinical Trial Registry Number ChiCTR2000033144.

Available only for authorised users

Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–76. https://doi.org/10.1093/europace/euab065.CrossRefPubMed

Brod C, Groth N, Rudeck M, Benziger CP. Trends In oral anticoagulation therapy in non-valvular atrial fibrillation patients at high-risk of stroke after the 2019 AHA/ACC/HRS update for the management of patients with atrial fibrillation guidelines. Circulation. 2022;145(Suppl 1):P107. https://doi.org/10.1161/circ.145.suppl_1.P107.CrossRef

January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, A.A.T.F. Members, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1):104–32. https://doi.org/10.1016/j.jacc.2019.01.011.CrossRefPubMed

Lip GY, Patel JV, Hughes E, Hart RG. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke. 2007;38(4):1229–37. https://doi.org/10.1161/01.STR.0000260090.90508.3e.CrossRefPubMed

Horikoshi Y, Goyagi T, Kudo R, Kodama S, Horiguchi T, Nishikawa T. The suppressive effects of landiolol administration on the occurrence of postoperative atrial fibrillation and tachycardia, and plasma IL-6 elevation in patients undergoing esophageal surgery: a randomized controlled clinical trial. J Clin Anesth. 2017;38:111–6. https://doi.org/10.1016/j.jclinane.2017.01.036.CrossRefPubMed

Lim GB. Arrhythmias: IL-6 and risk of atrial fibrillation in chronic kidney disease, Nature reviews. Cardiology. 2016;13(4):183. https://doi.org/10.1038/nrcardio.2016.23.CrossRefPubMed

Henningsen KM, Therkelsen SK, Bruunsgaard H, Krabbe KS, Pedersen BK, Svendsen JH. Prognostic impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation treated with electrical cardioversion. Scand J Clin Lab Invest. 2009;69(3):425–32. https://doi.org/10.1080/00365510802676848.CrossRefPubMed

Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108(24):3006–10. https://doi.org/10.1161/01.CIR.0000103131.70301.4F.CrossRefPubMed

Van Wagoner DR, Chung MK. Inflammation, inflammasome activation, and atrial fibrillation. Circulation. 2018;138(20):2243–6. https://doi.org/10.1161/CIRCULATIONAHA.118.036143.CrossRefPubMedPubMedCentral

10.

Kirchhof P, Ezekowitz MD, Purmah Y, Schiffer S, Meng IL, Camm AJ, et al. Effects of rivaroxaban on biomarkers of coagulation and inflammation: a post hoc analysis of the X-VeRT trial. TH Open. 2020;4(1):e20–32. https://doi.org/10.1055/s-0040-1701206.CrossRefPubMedPubMedCentral

11.

Daci A, Da Dalt L, Alaj R, Shurdhiqi S, Neziri B, Ferizi R, et al. Rivaroxaban improves vascular response in LPS-induced acute inflammation in experimental models. PLoS ONE. 2020;15(12): e0240669. https://doi.org/10.1371/journal.pone.0240669.CrossRefPubMedPubMedCentral

12.

Martins GL, Duarte RCF, Vieira ELM, Rocha NP, Figueiredo EL, Silveira FR, et al. Comparison of inflammatory mediators in patients with atrial fibrillation using warfarin or rivaroxaban. Front Cardiovasc Med. 2020;7:114. https://doi.org/10.3389/fcvm.2020.00114.CrossRef

13.

Zhang Y, Qian Q, Qian G, Sun G. Laboratory monitoring of rivaroxaban and assessment of its bleeding risk. Br J Biomed Sci. 2016;73(3):134–9. https://doi.org/10.1080/09674845.2016.1195151.CrossRefPubMed

14.

Sipila P, Lindbohm JV, Batty GD, Heikkila N, Vahtera J, Suominen S, et al. Severe infection and risk of cardiovascular disease: a multicohort study. Circulation. 2023;147(21):1582–93. https://doi.org/10.1161/Circulationaha.122.061183.CrossRefPubMed

15.

Katsoularis I, Fonseca-Rodriguez O, Farrington P, Jerndal H, Lundevaller EH, Sund M, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022;377: e069590. https://doi.org/10.1136/bmj-2021-069590.CrossRefPubMed

16.

Ramacciotti E, Barile Agati L, Calderaro D, Aguiar VCR, Spyropoulos AC, de Oliveira CCC, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet. 2022;399(10319):50–9. https://doi.org/10.1016/s0140-6736(21)02392-8.CrossRefPubMed

17.

Piazza G, Spyropoulos AC, Hsia J, Goldin M, Towner WJ, Go AS, et al. Rivaroxaban for prevention of thrombotic events, hospitalization, and death in outpatients with COVID-19: a randomized clinical trial. Circulation. 2023;147(25):1891–901. https://doi.org/10.1161/circulationaha.123.063901.CrossRefPubMedPubMedCentral

18.

Avezum Á, Oliveira Junior HA, Neves P, Alves LBO, Cavalcanti AB, Rosa RG, et al. Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE - COALITION VIII randomised clinical trial. EClinicalMedicine. 2023;60:102004. https://doi.org/10.1016/j.eclinm.2023.102004.CrossRefPubMedPubMedCentral

19.

Ananworanich J, Mogg R, Dunne MW, Bassyouni M, David CV, Gonzalez E, et al. Randomized study of rivaroxaban vs placebo on disease progression and symptoms resolution in high-risk adults with mild coronavirus disease 2019. Clin Infect Dis. 2022;75(1):e473–81. https://doi.org/10.1093/cid/ciab813.CrossRefPubMed

20.

Ahmed H, Whitaker H, Farewell D, Hippisley-Cox J, Noble S. Respiratory tract infection and risk of bleeding in oral anticoagulant users: self-controlled case series. BMJ (Clinical research ed). 2021;375: e068037. https://doi.org/10.1136/bmj-2021-068037.CrossRefPubMedPubMedCentral

21.

Lipardi C, Elliott CG, Sugarmann CL, Haskell L, Spyropoulos AC, Raskob GE, et al. Risk of severe bleeding with extended rivaroxaban to prevent venous thromboembolism in acute medically ill patients with bronchiectasis. Clin Appl Thromb Hemost. 2021;27:10760296211053316. https://doi.org/10.1177/10760296211053316.CrossRefPubMedPubMedCentral

22.

Gao H, Li Y, Sun H, Huang X, Chen H, Lin W, et al. Trough concentration deficiency of rivaroxaban in patients with nonvalvular atrial fibrillation leading to thromboembolism events. J Cardiovasc Pharmacol. 2022;80(6):869–76. https://doi.org/10.1097/fjc.0000000000001360.CrossRefPubMed

23.

Miklič M, Mavri A, Vene N, Söderblom L, Božič-Mijovski M, Pohanka A, et al. Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation. Eur J Clin Pharmacol. 2019;75(8):1069–75. https://doi.org/10.1007/s00228-019-02693-2.CrossRefPubMed

24.

Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014;64(11):1128–39. https://doi.org/10.1016/j.jacc.2014.05.065.CrossRefPubMedPubMedCentral

25.

Hill K, Sucha E, Rhodes E, Carrier M, Garg AX, Harel Z, et al. Risk of hospitalization with hemorrhage among older adults taking clarithromycin vs azithromycin and direct oral anticoagulants. JAMA Intern Med. 2020;180(8):1052–60. https://doi.org/10.1001/jamainternmed.2020.1835.CrossRefPubMed

26.

Fralick M, Juurlink DN, Marras T. Bleeding associated with coadministration of rivaroxaban and clarithromycin. Can Med Assoc J. 2016;188(9):669–72. https://doi.org/10.1503/cmaj.150580.CrossRef

27.

Clark NP, Delate T, Riggs CS, Witt DM, Hylek EM, Garcia DA, Warfarin-Associated Research Projects and Other Endeavors Consortium, et al. Warfarin interactions with antibiotics in the ambulatory care Setting. JAMA Intern Med. 2014;174(3):409–16. https://doi.org/10.1001/jamainternmed.2013.13957.CrossRefPubMed

28.

Kent AP, Brueckmann M, Fraessdorf M, Connolly SJ, Yusuf S, Eikelboom JW, et al. Concomitant oral anticoagulant and nonsteroidal anti-inflammatory drug therapy in patients with atrial fibrillation. J Am Coll Cardiol. 2018;72(3):255–67. https://doi.org/10.1016/j.jacc.2018.04.063.CrossRefPubMed

29.

Li XY, Gu ZC, Wang Z, Xu Q, Ma CL, Lv QZ. Mutant CYP3A4/5 correlated with clinical outcomes by affecting rivaroxaban pharmacokinetics and pharmacodynamics in patients with atrial fibrillation. Cardiovasc Drug Ther. 2023. https://doi.org/10.1007/s10557-023-07495-4.CrossRef

30.

Sychev DA, Sokolov AV, Reshetko OV, Fisenko VP, Sychev IN, Grishina EA, et al. Influence of ABCB1, CYP3A5 and CYP3A4 gene polymorphisms on prothrombin time and the residual equilibrium concentration of rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice. Pharmacogenet Genom. 2022;32(9):301–7. https://doi.org/10.1097/fpc.0000000000000483.CrossRef

31.

Wang Y, Chen M, Chen H, Wang F. Influence of ABCB1 gene polymorphism on rivaroxaban blood concentration and hemorrhagic events in patients with atrial fibrillation. Front Pharmacol. 2021;12: 639854. https://doi.org/10.3389/fphar.2021.639854.CrossRefPubMedPubMedCentral

32.

Testa S, Prandoni P, Paoletti O, Morandini R, Tala M, Dellanoce C, et al. Direct oral anticoagulant plasma levels’ striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the Cremona experience. J Thromb Haemost. 2020;18(6):1320–3. https://doi.org/10.1111/jth.14871.CrossRefPubMedPubMedCentral

Title: Rivaroxaban Plasma Concentration and Clinical Outcomes on Older Patients with Non-valvular Atrial Fibrillation and Pulmonary Infection
Authors: Yan Yu
Haobin Li
Jing Liu
Qing Liang
Juan Xie
Guangchun Sun
Publication date: 24-12-2023
Publisher: Springer International Publishing
Keywords: Rivaroxaban
Atrial Fibrillation
Thrombosis
Anticoagulant
Published in: American Journal of Cardiovascular Drugs / Issue 1/2024
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI: https://doi.org/10.1007/s40256-023-00622-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Rivaroxaban Plasma Concentration and Clinical Outcomes on Older Patients with Non-valvular Atrial Fibrillation and Pulmonary Infection

Abstract

Introduction

Objective

Methods

Results

Conclusions

Clinical Trials Registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Objective

Methods

Results

Conclusions

Clinical Trials Registration

Please log in to get access to this content

Other articles of this Issue 1/2024

Safety and Efficacy of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors After Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials

The Use of Sodium-Glucose Cotransporter-2 Inhibitors in Coronary Revascularization: Where Are We Now? A Systematic Review

Safety and Efficacy of Cangrelor in Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis

Cardioprotective strategies after ischemia–reperfusion injury

Intravenous Diltiazem Versus Metoprolol in Acute Rate Control of Atrial Fibrillation/Flutter and Rapid Ventricular Response: A Meta-Analysis of Randomized and Observational Studies

Iron dyshomeostasis and mitochondrial function in heart failure